Herbert J. Conrad, BS, MS

Chief Executive Officer, Sapphire Therapeutics

Herbert Conrad is currently Chief Executive Officer of Sapphire Therapeutics. Mr. Conrad was US president of Roche Pharmaceuticals a company he was affiliated with for 33 years. He has served on the Boards of Dura, UroCor, Sicor, GenVec, and Bone Care International. Mr. Conrad is currently on the Boards of Savient Pharmaceuticals, Celldex Therapeutics, and Symphony Evolution.

Mr. Conrad earned his undergraduate and graduate degrees in Pharmacy from the Brooklyn College of Pharmacy. He also has received a Doctorate in Humane Letters (Honorary) from Long Island University.